^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    lenalidomide

    i
    Other names: IMiD3, CDC 5013, CC-5013, CDC-501, CDC-5013, IMiD-1, IMiD-3, ENMD-0997, CC 5013, CDC 5013, ENMD 0997
    Company:
    Generic mfg.
    Drug class:
    TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor
    Related drugs:
    1d
    KarMMa-9: A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (clinicaltrials.gov)
    P3, N=79, Active, not recruiting, Celgene | N=618 --> 79 | Trial completion date: Aug 2025 --> Nov 2029
    Enrollment change • Trial completion date
    |
    lenalidomide • cyclophosphamide • fludarabine IV • Abecma (idecabtagene vicleucel)
    1d
    GEM-BELA-VRd: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, PETHEMA Foundation | Completed --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • bortezomib • dexamethasone • melphalan • Blenrep (belantamab mafodotin-blmf)
    2d
    Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL (clinicaltrials.gov)
    P2, N=50, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • lenalidomide • Inokai (orelabrutinib)
    2d
    BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    lenalidomide • cyclophosphamide • fludarabine IV
    2d
    ORBIT: Optimizing Reversal of HIV Latency With Combination Therapy (clinicaltrials.gov)
    P1/2, N=49, Active, not recruiting, Erasmus Medical Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD4 (CD4 Molecule)
    |
    lenalidomide • Farydak (panobinostat)
    2d
    GEM-BELA-VRd: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients (clinicaltrials.gov)
    P2, N=50, Completed, PETHEMA Foundation | Not yet recruiting --> Completed
    Trial completion
    |
    lenalidomide • bortezomib • dexamethasone • melphalan • Blenrep (belantamab mafodotin-blmf)
    2d
    ATLAS: Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma (clinicaltrials.gov)
    P3, N=180, Active, not recruiting, University of Chicago | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Nov 2025 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    lenalidomide • carfilzomib • dexamethasone
    3d
    KarMMa-2: An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (clinicaltrials.gov)
    P2, N=312, Completed, Celgene | Active, not recruiting --> Completed | Trial completion date: Oct 2025 --> Jan 2026 | Trial primary completion date: Oct 2025 --> Jan 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    lenalidomide • Abecma (idecabtagene vicleucel) • Talvey (talquetamab-tgvs)
    3d
    Accelerated synthesis of immunomodulatory imide drugs and their derivatives via continuous flow chemistry. (PubMed, Commun Chem)
    Herein, we report the synthesis of lenalidomide (63% overall yield) and pomalidomide (62% overall yield) using an integrated continuous flow platform with residence times of 42 minutes and 52 minutes, respectively. The products are obtained without the need for column chromatography, and both immunomodulatory imide drugs (IMiDs) can be accessed from a common intermediate through our developed route. Furthermore, we explore the synthesis of CRBN ligand-linkers under continuous flow, affording a series of derivatives with diverse properties in yields exceeding 90%.
    Journal
    |
    CRBN (Cereblon)
    |
    lenalidomide • pomalidomide
    3d
    MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, University of Arkansas | Initiation date: Apr 2026 --> Jul 2026
    Trial initiation date
    |
    clonoSEQ
    |
    lenalidomide • Darzalex (daratumumab) • melphalan • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    4d
    Neutrophil extracellular trap-related genes in PTCL: identification, prognosis and drug interaction prediction via bioinformatics-machine learning. (PubMed, Hematology)
    Potential therapeutic agents (e.g. capivasertib, lenalidomide) were predicted, and lenalidomide may represent a feasible initial treatment option for PTCL, with an objective response rate (ORR) of 40.0% and a maximum survival duration exceeding 50 months. NET-RGs play crucial roles in diagnosis, prognosis, and TME regulation, and lenalidomide, a putative TNF-targeting agent, may represent a feasible initial treatment option in PTCL.
    Journal
    |
    AKT2 (V-akt murine thymoma viral oncogene homolog 2) • IRF1 (Interferon Regulatory Factor 1) • MAPK14 (Mitogen-Activated Protein Kinase 14)
    |
    lenalidomide • Truqap (capivasertib)
    4d
    CAC-PPCL-001: A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia (clinicaltrials.gov)
    P2, N=20, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Trial primary completion date: Apr 2025 --> Jun 2026
    Trial primary completion date
    |
    lenalidomide • bortezomib • dexamethasone